Matthew Herper covers medical innovation — both its promise and its perils. SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He ...
Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results